Display options
Cite
Zhang Q, Li R, Chen X, et al. Effect of weekly or daily dosing regimen of Gefitinib in mouse models of lung cancer. Oncotarget. 2017;8(42):72447-72456doi: 10.18632/oncotarget.19785.
Zhang, Q., Li, R., Chen, X., Lee, S. B., Pan, J., Xiong, D., Hu, J., Miller, M. S., Szabo, E., Lubet, R. A., Wang, Y., & You, M. (2017). Effect of weekly or daily dosing regimen of Gefitinib in mouse models of lung cancer. Oncotarget, 8(42), 72447-72456. https://doi.org/10.18632/oncotarget.19785
Zhang, Qi, et al. "Effect of weekly or daily dosing regimen of Gefitinib in mouse models of lung cancer." Oncotarget vol. 8,42 (2017): 72447-72456. doi: https://doi.org/10.18632/oncotarget.19785
Zhang Q, Li R, Chen X, Lee SB, Pan J, Xiong D, Hu J, Miller MS, Szabo E, Lubet RA, Wang Y, You M. Effect of weekly or daily dosing regimen of Gefitinib in mouse models of lung cancer. Oncotarget. 2017 Aug 02;8(42):72447-72456. doi: 10.18632/oncotarget.19785. eCollection 2017 Sep 22. PMID: 29069801; PMCID: PMC5641144.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2017 Aug 02;8(42):72447-72456. doi: 10.18632/oncotarget.19785. eCollection 2017 Sep 22.

Effect of weekly or daily dosing regimen of Gefitinib in mouse models of lung cancer.

Oncotarget

Qi Zhang, Ruichao Li, Xu Chen, Sang Beom Lee, Jing Pan, Donghai Xiong, Jiaqi Hu, Mark Steven Miller, Eva Szabo, Ronald A Lubet, Yian Wang, Ming You

Affiliations

  1. Cancer Center, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
  2. Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
  3. Chemopreventive Agent Development Research Group, Division of Cancer Prevention, National Cancer Institute, Rockville, MD 20850, USA.

PMID: 29069801 PMCID: PMC5641144 DOI: 10.18632/oncotarget.19785

Abstract

Gefitinib showed response in phase II clinical trials and with better clinical response in lung cancer with activating mutations in the tyrosine kinase domain of the EGFR. Questions of toxicity and potential dosing regimens impede the use in a prevention setting. This study will provide scientific evidence for the utility of testing and comparing weekly and daily dosing regimens in clinical trials. We employed the adenocarcinoma (AD) and squamous cell carcinoma (SCC) models to compare the efficacy of Gefitinib in daily or weekly dosing regimens. We also assessed the effectiveness of Gefitinib in altering growth of the H3255 xenograft. Bioluminescent imaging (BLI) and tumor size was evaluated. Relative expression of phospho-EGFR, phospho-ERK and phospho-AKT in the xenograft were evaluated by Western Blot analysis. In the lung AD model, Gefitinib showed significant inhibition of tumor load when treated with weekly or weekly intermittent dosing regimens in AJ/p53

Keywords: Gefitinib; daily; intermittent; lung cancer; weekly

Conflict of interest statement

CONFLICTS OF INTEREST No potential conflicts of interest were disclosed by any authors of this manuscript.

References

  1. J Thorac Oncol. 2015 May;10(5):838-43 - PubMed
  2. Clin Cancer Res. 2016 May 1;22(9):2139-45 - PubMed
  3. Cancer Prev Res (Phila). 2013 May;6(5):448-54 - PubMed
  4. Clin Cancer Res. 2004 Feb 15;10(4):1212-8 - PubMed
  5. Eur J Cancer. 2010 Jul;46(11):2010-9 - PubMed
  6. JAMA. 2003 Oct 22;290(16):2149-58 - PubMed
  7. Am J Pathol. 2003 Jul;163(1):303-12 - PubMed
  8. J Dermatol Sci. 2011 Dec;64(3):163-73 - PubMed
  9. Oncogene. 2009 Aug;28 Suppl 1:S24-31 - PubMed
  10. J Clin Oncol. 2013 Nov 20;31(33):4169-71 - PubMed
  11. Mol Cancer Res. 2006 Dec;4(12):971-81 - PubMed
  12. Cancer Chemother Pharmacol. 2007 Mar;59(4):467-75 - PubMed
  13. Cancer Res. 2004 Mar 1;64(5):1647-54 - PubMed
  14. Expert Opin Biol Ther. 2005 Sep;5(9):1165-74 - PubMed
  15. Cancer Prev Res (Phila). 2017 Feb;10 (2):133-141 - PubMed
  16. J Clin Invest. 2004 Jun;113(11):1550-9 - PubMed
  17. J Immunol. 2005 Apr 15;174(8):5047-56 - PubMed
  18. Science. 2004 Jun 4;304(5676):1497-500 - PubMed
  19. Genes Cancer. 2012 Jul;3(7-8):467-80 - PubMed
  20. Mayo Clin Proc. 2008 May;83(5):584-94 - PubMed
  21. Nat Rev Clin Oncol. 2011 Feb;8(2):68-70 - PubMed
  22. Cancer. 2006 Sep 1;107(5):1034-41 - PubMed
  23. Science. 2004 Aug 20;305(5687):1163-7 - PubMed
  24. Ann Oncol. 2004 May;15(5):786-92 - PubMed
  25. Neuro Oncol. 2011 Dec;13(12):1364-9 - PubMed
  26. Curr Treat Options Oncol. 2005 Jan;6(1):75-81 - PubMed
  27. Oncotarget. 2015 Nov 17;6(36):38458-68 - PubMed
  28. PLoS One. 2012;7(5):e37207 - PubMed
  29. Bioorg Med Chem Lett. 2001 Jul 23;11(14):1911-4 - PubMed
  30. CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30 - PubMed
  31. Crit Rev Oncol Hematol. 1995 Jul;19(3):183-232 - PubMed
  32. Ann Oncol. 2012 Apr;23 (4):1023-9 - PubMed
  33. Cancer Res. 2002 Oct 15;62(20):5749-54 - PubMed
  34. Expert Opin Ther Targets. 2012 Jan;16(1):15-31 - PubMed

Publication Types